Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity

S. Ager, B. H K Nilson, F. J. Morling, Kah-Whye Peng, F. L. Cosset, Stephen J Russell

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Five different single-chain antibody fragments (scFv) against human cell-surface antigens were displayed on murine ecotropic retroviral vectors by fusing them to the Moloney SU envelope glycoprotein. The spacing between the scFv and the SU glycoprotein was varied by fusing the scFv to residue +7 or to residue +1 of Moloney SU and by inserting linker sequences of different lengths between the domains. All of the chimeric envelopes were efficiently incorporated into vector particles and could bind to human cells through their displayed antibody fragments, but did not infect them. The spacing between the scFvs and the SU glycoproteins had no significant effect on the efficiency of envelope expression or viral incorporation and did not affect the binding properties of the chimeric envelopes, nor did it influence the efficiency of targeted gene delivery to human cells by scFv-displaying vectors. However, on murine fibroblasts the infectivity of vectors incorporating the chimeric envelopes was strongly influenced by the length of the interdomain spacer. The titers were very low when the single-chain antibodies were fused through a tripeptide linker to SU residue +7 and were greatly enhanced (up to 105-fold) when they were fused to SU residue +1 through a heptapeptide linker. These results point to the importance of steric interactions between the domains of chimeric envelope glycoproteins and may have implications for retroviral vector design for human gene therapy.

Original languageEnglish (US)
Pages (from-to)2157-2164
Number of pages8
JournalHuman Gene Therapy
Volume7
Issue number17
StatePublished - Nov 10 1996
Externally publishedYes

Fingerprint

Immunoglobulin Fragments
Glycoproteins
Single-Chain Antibodies
Surface Antigens
Genetic Therapy
Fibroblasts
Genes

ASJC Scopus subject areas

  • Genetics

Cite this

Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity. / Ager, S.; Nilson, B. H K; Morling, F. J.; Peng, Kah-Whye; Cosset, F. L.; Russell, Stephen J.

In: Human Gene Therapy, Vol. 7, No. 17, 10.11.1996, p. 2157-2164.

Research output: Contribution to journalArticle

Ager, S. ; Nilson, B. H K ; Morling, F. J. ; Peng, Kah-Whye ; Cosset, F. L. ; Russell, Stephen J. / Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity. In: Human Gene Therapy. 1996 ; Vol. 7, No. 17. pp. 2157-2164.
@article{1022b08e9f9f405abf0a4db8648bcc00,
title = "Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity",
abstract = "Five different single-chain antibody fragments (scFv) against human cell-surface antigens were displayed on murine ecotropic retroviral vectors by fusing them to the Moloney SU envelope glycoprotein. The spacing between the scFv and the SU glycoprotein was varied by fusing the scFv to residue +7 or to residue +1 of Moloney SU and by inserting linker sequences of different lengths between the domains. All of the chimeric envelopes were efficiently incorporated into vector particles and could bind to human cells through their displayed antibody fragments, but did not infect them. The spacing between the scFvs and the SU glycoproteins had no significant effect on the efficiency of envelope expression or viral incorporation and did not affect the binding properties of the chimeric envelopes, nor did it influence the efficiency of targeted gene delivery to human cells by scFv-displaying vectors. However, on murine fibroblasts the infectivity of vectors incorporating the chimeric envelopes was strongly influenced by the length of the interdomain spacer. The titers were very low when the single-chain antibodies were fused through a tripeptide linker to SU residue +7 and were greatly enhanced (up to 105-fold) when they were fused to SU residue +1 through a heptapeptide linker. These results point to the importance of steric interactions between the domains of chimeric envelope glycoproteins and may have implications for retroviral vector design for human gene therapy.",
author = "S. Ager and Nilson, {B. H K} and Morling, {F. J.} and Kah-Whye Peng and Cosset, {F. L.} and Russell, {Stephen J}",
year = "1996",
month = "11",
day = "10",
language = "English (US)",
volume = "7",
pages = "2157--2164",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "17",

}

TY - JOUR

T1 - Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity

AU - Ager, S.

AU - Nilson, B. H K

AU - Morling, F. J.

AU - Peng, Kah-Whye

AU - Cosset, F. L.

AU - Russell, Stephen J

PY - 1996/11/10

Y1 - 1996/11/10

N2 - Five different single-chain antibody fragments (scFv) against human cell-surface antigens were displayed on murine ecotropic retroviral vectors by fusing them to the Moloney SU envelope glycoprotein. The spacing between the scFv and the SU glycoprotein was varied by fusing the scFv to residue +7 or to residue +1 of Moloney SU and by inserting linker sequences of different lengths between the domains. All of the chimeric envelopes were efficiently incorporated into vector particles and could bind to human cells through their displayed antibody fragments, but did not infect them. The spacing between the scFvs and the SU glycoproteins had no significant effect on the efficiency of envelope expression or viral incorporation and did not affect the binding properties of the chimeric envelopes, nor did it influence the efficiency of targeted gene delivery to human cells by scFv-displaying vectors. However, on murine fibroblasts the infectivity of vectors incorporating the chimeric envelopes was strongly influenced by the length of the interdomain spacer. The titers were very low when the single-chain antibodies were fused through a tripeptide linker to SU residue +7 and were greatly enhanced (up to 105-fold) when they were fused to SU residue +1 through a heptapeptide linker. These results point to the importance of steric interactions between the domains of chimeric envelope glycoproteins and may have implications for retroviral vector design for human gene therapy.

AB - Five different single-chain antibody fragments (scFv) against human cell-surface antigens were displayed on murine ecotropic retroviral vectors by fusing them to the Moloney SU envelope glycoprotein. The spacing between the scFv and the SU glycoprotein was varied by fusing the scFv to residue +7 or to residue +1 of Moloney SU and by inserting linker sequences of different lengths between the domains. All of the chimeric envelopes were efficiently incorporated into vector particles and could bind to human cells through their displayed antibody fragments, but did not infect them. The spacing between the scFvs and the SU glycoproteins had no significant effect on the efficiency of envelope expression or viral incorporation and did not affect the binding properties of the chimeric envelopes, nor did it influence the efficiency of targeted gene delivery to human cells by scFv-displaying vectors. However, on murine fibroblasts the infectivity of vectors incorporating the chimeric envelopes was strongly influenced by the length of the interdomain spacer. The titers were very low when the single-chain antibodies were fused through a tripeptide linker to SU residue +7 and were greatly enhanced (up to 105-fold) when they were fused to SU residue +1 through a heptapeptide linker. These results point to the importance of steric interactions between the domains of chimeric envelope glycoproteins and may have implications for retroviral vector design for human gene therapy.

UR - http://www.scopus.com/inward/record.url?scp=0029846575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029846575&partnerID=8YFLogxK

M3 - Article

C2 - 8934229

AN - SCOPUS:0029846575

VL - 7

SP - 2157

EP - 2164

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 17

ER -